Inflammatory breast cancer (IBC) is often characterized by overexpression of epidermal growth factor receptors 1 and/or 2 (ErbB1, ErbB2) that activate downstream survival pathways phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) and MAPK (66). This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.